- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Govt amends CSR norms to allow pharma firms to contribute to COVID-19 RnD; Details
New Delhi: Through a recent Gazette notification, the Government has amended the Companies Corporate Social Responsibility Policy (CSR) Rules, 2014 to include Research and Development (R&D) spending on new vaccines, drugs, medical devices related to COVID-19; and allow pharmaceutical and medical device companies to support R&D activities to find a cure for the virus, collaboratively, in publicly funded institutions.
The government is allowing investment towards such efforts to be considered as fulfillment of a company's Corporate Social Responsibility (CSR) obligations.
As per the Gazette notification;
"Any company engaged in research and development activity of new vaccine, drugs and medical devices in their normal course of business may undertake research and development activity of new vaccine, drugs and medical devices related to COVID-19 for financial years 2020-21, 2021-22 and 2022-23 subject to the conditions."
The notification further stated the conditions, wherein, the spending will have to be made in financial years 2020-21, 2021-22, and 2022-23 and the R&D should be carried out in collaboration with the government nominated institutes or organizations.
"Such research and development activities shall be carried out in collaboration with any of the institutes or organizations mentioned in item (ix) of Schedule VII to the Act. And, details of such activity shall be disclosed separately in the Annual Report on CSR included in the Board's Report." the notification read.
The item (ix) of Schedule VII includes public-funded Universities, Indian Institute of Technology (IITs), National Laboratories and Autonomous Bodies (established under the auspices of Indian Council of Agricultural Research (ICAR), Indian Council of Medical Research (ICMR), Council of Scientific and Industrial Research (CSIR), Department of Atomic Energy (DAE), Defence Research and Development Organisation (DRDO), Department of Biotechnology (DBT), Department of Science and Technology (DST), Ministry of Electronics and Information Technology.
The amendment has also temporarily removed a provision that would have excluded "activities undertaken in pursuance of its (the company's) normal course of business" from being considered as CSR activities.
In the normal course, such institutes and organizations, "or any other" central or state fund for socio-economic development and relief, as well as funds for the welfare of Scheduled Castes, Scheduled Tribes, other backward classes, minorities, and women.
However, with the amendment, Schedule VII will substitute it with incubators or research and development projects in the field of science, technology, engineering, and medicine that are funded by the central or state Government, a Public Sector Undertaking or any government agency.
Also Read: India Will Get COVID-19 Vaccine By 2020 End: Union Health Minister
For more details click on the link below-
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751